Lb Pharmaceuticals (LBRX) Total Current Liabilities (2024 - 2026)

Lb Pharmaceuticals' Total Current Liabilities history runs 3 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• In Q1 2026, Total Current Liabilities changed N/A year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $10.9 million (changed N/A YoY), while the FY2025 annual figure was $7.4 million, down 8.23% from the prior year.
• Total Current Liabilities was $10.9 million for Q1 2026 at Lb Pharmaceuticals, up from $7.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $10.9 million in Q1 2026 to a low of $6.6 million in Q3 2025.
• Historically, Total Current Liabilities has averaged $8.3 million across 3 years, with a median of $7.8 million in 2024.
• Biggest YoY gain for Total Current Liabilities was 8.23% in 2025; the steepest drop was 8.23% in 2025.
• A 3-year view of Total Current Liabilities shows it stood at $8.1 million in 2024, then dropped by 8.23% to $7.4 million in 2025, then surged by 46.55% to $10.9 million in 2026.
• The last three Total Current Liabilities figures came in at $10.9 million (Q1 2026), $7.4 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.